Pharmaceuticals Hong Kong

Hong Kong Cell Based Immunotherapy Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Hong Kong Cell Based Immunotherapy Market Analysis Industry Trends and Forecast to 2034: Segmented by (By Therapy Type, By Indication, By End User, By Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Hong Kong · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $33.0 Mn Placeholder estimate
Estimate 2025 $40.9 Mn 0.2% of the global market
Projected 2034 $283.5 Mn 593.1% Adds $242.6 Mn over 9 forecast years
CAGR 2025–2034 24.0% Faster than 91% of 180 Pharmaceuticals markets here
Key players 5
  • Hong Kong is 0.16% of the global market.
  • In APAC, the largest is China at $2.07 Bn.
  • Fastest growing: India at 26% a year.
  • Hong Kong ranks 6th of 9 by size in APAC.

Market size projection

Hong Kong

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$242.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Cell Based Immunotherapy Market market size by year, Hong Kong
YearMarket sizeChange that yearSince 2025
2024 (estimate) $33.0 Mn — —
2025 (base) $40.9 Mn +$7.9 Mn —
2026 (forecast) $50.7 Mn +$9.8 Mn +24%
2027 (forecast) $62.9 Mn +$12.2 Mn +53.8%
2028 (forecast) $78.0 Mn +$15.1 Mn +90.7%
2029 (forecast) $96.7 Mn +$18.7 Mn +136.4%
2030 (forecast) $119.9 Mn +$23.2 Mn +193.2%
2031 (forecast) $148.7 Mn +$28.8 Mn +263.5%
2032 (forecast) $184.4 Mn +$35.7 Mn +350.8%
2033 (forecast) $228.6 Mn +$44.2 Mn +459%
2034 (forecast) $283.5 Mn +$54.9 Mn +593.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Hong Kong Cell Based Immunotherapy Market Analysis at a glance
Market size, 2025$40.9 Mn placeholder estimate
Forecast, 2034$283.5 Mn placeholder estimate
Growth (CAGR), 2025–203424.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTherapy type, indication and end user (see all)
Key playersNovartis AG, Gilead Sciences, Inc., Dendreon Pharmaceuticals LLC, AbbVie Inc., Bristol-Myers Squibb (see all)
Regulator in Hong KongDrug OfficeSource: Drug Office, Department of Health. Checked 14 Nov 2026.
Active clinical trials251 in Hong KongSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 9 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Hong Kong Cell Based Immunotherapy Market Analysis Executive Summary

Immunotherapy aims at employing immune cells in the treatment of cancer as they directly locate and destroy cancer cells. This procedure is accomplished by harvesting specific immune cells from a patient, stimulating or altering them in one way or another, culturing them to increase their numbers, and then reintroducing them into the patient. In 2025, the U.S. is projected to see 1.96 million new cancer cases and 610,000 cancer deaths. Among all these therapies this field has to offer, the CAR T-cell treatment that includes Kymriah for B-cell precursor acute lymphoblastic leukemia and diffuse large B-cell lymphoma, Yescarta for diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma, and Tecartus for mantle cell lymphoma for blood cancer is in the forefront. Therefore, the cell-based immunotherapy market is still emerging but is expected to develop quickly.

Such growth is due to a progress in technology and a need for new approaches in cancer therapy. Some of the key players in the market are Novartis, Gilead science, Bristol-Myers Squibb, and bluebird Bio; however, there are numerous startups participating in the market. There are threats like a high degree of capital intensity, complicated production procedures, and legal restrictions, but the sector is growing owing to innovation and a higher focus on healthcare needs and facilities enhancement throughout NA, EU, and Asia-Pacific areas.

Bar chart: Hong Kong Cell Based Immunotherapy market size, 2024–2034, placeholder estimates. $33.0 Mn in 2024, $40.9 Mn in 2025 and $283.5 Mn in 2034, 24.0% CAGR.
Hong Kong Cell Based Immunotherapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Hong Kong Cell Based Immunotherapy Market Dynamics

Market Growth Drivers

The cell-based immunotherapy industry is on the growth trajectory for several reasons. The geriatric population is one of the leading modalities of cancer incidences and this makes them to seek for cell-based immunotherapy. Progress in these therapies is also fueling market growth and an increase in clinical trials and changing from personalized (allogeneic, off-the-shelf) treatments. Also, greater R & D spending by major players is expanding product portfolios and clearances. Regionally, the market is expanding steadily in the developed regions such as North America attributed to high incidences of cancer and advancement in technology while the Asia Pacific region is expected to mark growth in the future years.
Opportunities

Thus, the future of cell-based immunotherapy seems to be bright given the following aspects: To overcome the obstacles of managing solid tumors, researchers are now working on targeted therapy for individual tumor mutations. The advancement of other techniques such as CRISPR-Cas9 enhances CAR T-cell therapies while Natural Killer (NK) cell therapies provide new hope for patients with chronic diseases who do not respond to other treatment options. Dendritic cell vaccines are also under focus for their immunomodulating capacities and consideration when it comes to cancer. Further, the utilization of cell-based therapies alongside other treatments, including checkpoint inhibitors, is under investigation for enhanced outcomes.

Market Restrains

The cell-based immunotherapy market faces several issues as follows. The lack of sound clinical evidence has placed these therapies under a lot of restrictions when it comes to their uptake by patients and practitioners particularly in the developing world. The average cost of treating such patients is high and this acts as a major hurdle particularly in the developing nations where there are scarce resources to allocation towards health care. The combination of product types within the movement, and the refined and intricate steps needed to create and assemble low-volume/high-technology goods make simple production and high quality difficult to achieve. New therapies face market entry constraints by being subject to complex and lengthy regulatory processes as well as additional strict demands. Lack of awareness and knowledge on the part of patients and practitioners aside from less developed organizations in the developing world also remain problematic. Also, there are always fear instances where one may get severe immune reactions, and this will make the patients and the health practitioners to be overly cautious in their choice of these treatments.

Competitive Landscape for Cell Based Immunotherapy Market in Hong Kong

Key Players

Recent Developments

October 2025, CDSCO approves ImmunoACT’s CAR-T cell therapy. NexCAR19, which became the first CAR T-cell therapy in India.

February 2024, Tumor-infiltrating lymphocyte therapy has received FDA approval for certain patients with metastatic melanoma.

Mergers and Acquisitions

August 2024, Ikena Oncology, a company specializing in targeted oncology, acquired the biotech startup Pionyr Immunotherapeutic through an all-stock transaction valued at around $43 million.

February 2024, Novartis revealed its acquisition of MorphoSys AG for about $2.9 billion (€2.7 billion). This strategic acquisition is set to strengthen Novartis's oncology portfolio by incorporating MorphoSys's innovative cancer therapies, including pelabresib, an investigational BET inhibitor, and tulmimetostat, a dual inhibitor of EZH2 and EZH1.

Healthcare Policies and Regulatory Landscape for Cell Based Immunotherapy Market in Hong Kong

Cell Based Immunotherapy in Hong Kong: rules, payment and research

Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health.⁠[1] Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government.⁠[2] ClinicalTrials.gov lists 251 studies on Cell Based Immunotherapy that are recruiting, active or about to start in Hong Kong.⁠[3]

[1] Drug Office, Department of Health. Checked 14 Nov 2026.

[2] Hospital Authority. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 9 Nov 2026.

Policy changes and Reimbursement scenario

The development of adopting cell-based immunotherapies is influenced by new policy and reimbursement trends. While approvals for therapies such as Kymriah and Yescarta are taking place, the approval is still very lengthy. Further, reimbursement challenges arise from high costs of treatment, with possible solutions like addition of new CMS billing codes, and implementation of value-based contractual approaches. Reimbursement policies differ around the globe and use of MEAs also influence access to the medicines. When the market evolves, other essential aspects that must be addressed include the maintenance of strong reimbursement structures and the promotion of other-party cooperation as key ways to sustain affordable access to these new technologies.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Cell Based Immunotherapy right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 9 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Cell Based Immunotherapy in context

Hong Kong compared

  • People aged 65 and over: 23.7% of people (2025). World: 10.4% of people (2025). 2nd highest of the 16 countries we cover in APAC.[1]

[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Cell Based Immunotherapy market in Hong Kong?
Placeholder estimate: about $40.9 Mn in 2025, rising to about $283.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Cell Based Immunotherapy market in Hong Kong growing?
Placeholder estimate: about 24.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Cell Based Immunotherapy market report cover?
The report splits the market by therapy type (Autologous Cellular Immunotherapy, Chimeric Antigen Receptor (CAR) T-Cell Therapy, Dendritic Cell-based Vaccine Therapy), indication (B-cell Malignancies, Solid Tumors, Other Cancers) and end user (Hospitals, Ambulatory Surgical Centres, Specialized Cancer Institutes).
Who are the key players in the Cell Based Immunotherapy market?
Key players include Novartis AG, Gilead Sciences, Inc., Dendreon Pharmaceuticals LLC, AbbVie Inc. and Bristol-Myers Squibb.
What is driving the Cell Based Immunotherapy market?
The cell-based immunotherapy industry is on the growth trajectory for several reasons. The geriatric population is one of the leading modalities of cancer incidences and this makes them to seek for cell-based immunotherapy.
Who regulates Cell Based Immunotherapy in Hong Kong?
Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health. Source: Drug Office, Department of Health. Checked 14 Nov 2026.
How is healthcare paid for in Hong Kong?
Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government. Source: Hospital Authority. Checked 14 Nov 2026.
How many clinical trials on Cell Based Immunotherapy are running in Hong Kong?
251 studies are recruiting, active or about to start in Hong Kong, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 9 Nov 2026.
How much research is published on Cell Based Immunotherapy?
PubMed lists 21,014 papers on Cell Based Immunotherapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 9 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Hong Kong

See all

Related on biologics and biosimilars and oncology

See the topic